Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

OrthoLogic partnership opportunities

This article was originally published in The Gray Sheet

  • News

Executive Summary

Firm's Chrysalis BioTechnology acquisition for $27.5 mil. in cash and stock (plus up to $7 mil. in milestones) stems from an earlier licensing pact for development-phase, Chrysalin synthetic peptide-based therapeutics for orthopedic indications. The purchase provides rights beyond orthopedics: OrthoLogic is considering partnering with a device firm to market a Chrysalin-based cardiovascular drug that could be delivered via catheter for ischemia, CEO Thomas Trotter said April 29. The firm also is pondering partnerships to speed development of five Chrysalin-based products for orthopedic indications (1"The Gray Sheet" Oct. 13, 2003, p. 12)...

Table

View full table

Tags:
Latest Headlines

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

See All
UsernamePublicRestriction

Register

MT020160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By